AML1-MTG8 antibody

Details for Product No. ABIN965546
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Reactivity
Human
Host
Rabbit
Clonality
Polyclonal
Application
Immunohistochemistry (IHC)
Pubmed 9 references available
Quantity 0.1 mg
Options
Shipping to United States (Change)
Availability Will be delivered in 5 to 7 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN965546
302.50 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c)
Purification Purified by antigen-specific affinity chromatography.
Background AML1-MTG8(acute myelogenous leukemia 1 translocation 1 protein isoform MTG8c) is a putative zinc finger transcription factor and oncoprotein. In acute myeloid leukemia, especially in the M2 subtype, the t(8,21)(q22,q22) translocation is one of the most frequent karyotypic abnormalities. The translocation produces a chimeric gene made up of the 5'-region of the RUNX1 gene fused to the 3'-region of this gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation. Several transcript variants encoding multiple isoforms have been found for this gene.
Application Notes ELISA, Western blotting: 1µg/ml for 2hrs.
Restrictions For Research Use only
Format Liquid
Buffer This antibody is stored in PBS, 50% glycerol
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Product cited in: Tonks, Pearn, Tonks et al.: "The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells." in: Blood, Vol. 101, Issue 2, pp. 624-32, 2003 (PubMed).

Follows, Tagoh, Lefevre et al.: "Epigenetic consequences of AML1-ETO action at the human c-FMS locus." in: The EMBO journal, Vol. 22, Issue 11, pp. 2798-809, 2003 (PubMed).

McGhee, Bryan, Elliott et al.: "Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism." in: Journal of cellular biochemistry, Vol. 89, Issue 5, pp. 1005-18, 2003 (PubMed).

Chevallier, Corcoran, Lennon et al.: "ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein." in: Blood, Vol. 103, Issue 4, pp. 1454-63, 2004 (PubMed).

Martinez, Drescher, Riehle et al.: "The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells." in: BMC cancer, Vol. 4, pp. 44, 2004 (PubMed).

Zhang, Kalkum, Yamamura et al.: "E protein silencing by the leukemogenic AML1-ETO fusion protein." in: Science (New York, N.Y.), Vol. 305, Issue 5688, pp. 1286-9, 2004 (PubMed).

Lausen, Cho, Liu et al.: "The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO." in: The Journal of biological chemistry, Vol. 279, Issue 47, pp. 49281-8, 2004 (PubMed).

Lindberg, Olsson, Persson et al.: "The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation." in: Experimental hematology, Vol. 33, Issue 2, pp. 189-98, 2005 (PubMed).

Liu, Shen, Huynh et al.: "Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia." in: Cancer research, Vol. 65, Issue 4, pp. 1277-84, 2005 (PubMed).

Validation Images
Did you look for something else?
back to top